<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00970879</url>
  </required_header>
  <id_info>
    <org_study_id>IRD-Sidaction-01</org_study_id>
    <nct_id>NCT00970879</nct_id>
  </id_info>
  <brief_title>Prevention of Pregnancy-associated Malaria in HIV-infected Women: Cotrimoxazole Prophylaxis Versus Mefloquine</brief_title>
  <acronym>PACOME</acronym>
  <official_title>Prevention of Pregnancy-associated Malaria in HIV-infected Women : Randomised Controlled Trial Testing Cotrimoxazole Prophylaxis Versus Intermittent Preventive Treatment With Mefloquine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche pour le Developpement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sidaction</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saint Antoine University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National University Hospital, Cotonou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université d'Abomey-Calavi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Benin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recherche pour le Developpement</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of cotrimoxazole prophylaxis in
      prevention of malaria during pregnancy in HIV-infected women, compared to intermittent
      preventive treatment with mefloquine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Malaria infection during pregnancy can have adverse effects on both mother and fetus,
      including maternal anaemia and low birth weight which are responsible for mother and infant
      mortality. It is a particular problem for women in their first and second pregnancies and for
      women who are HIV-positive. Maternal HIV infection potentiates many of these adverse effects.
      In HIV-infected women, the World Health Organization (WHO) advocates the use of
      insecticide-treated bednets, and drugs : If the CD4 cell count is below 350/mm3 or the HIV
      disease is in WHO stage 2, 3 or 4, cotrimoxazole prophylaxis for the prevention of
      pneumocystosis and toxoplasmosis is indicated, that is assumed to also protect those women
      from malaria. Otherwise, they have to receive at least three doses of intermittent preventive
      treatment (IPT), most commonly with sulfadoxine-pyrimethamine (SP) given at the antenatal
      care visits. If IPT with SP has been a subject of many investigations, cotrimoxazole efficacy
      has never been assessed in prevention of malaria during pregnancy.

      The investigators aim to evaluate the efficacy of cotrimoxazole prophylaxis in prevention of
      malaria during pregnancy in HIV-infected women. The investigators postulate that
      cotrimoxazole prophylaxis is not inferior to IPT in all women, unrelated to their CD4 cell
      count. In the control arm, the investigators will use mefloquine as IPT. The safety and
      efficacy of this drug have already been assessed in HIV-negative patients (NCT00274235).

      A randomized controlled trial will be conducted in five hospitals in Benin. Pregnant women
      will be enrolled both in the Antenatal Care unit and in the Infectious Diseases unit of each
      setting. All women will receive insecticide-treated bednets at enrolment. Randomization will
      be stratified by hospital and CD4 cell count range. Women assigned to cotrimoxazole will
      receive cotrimoxazole prophylaxis daily during all the course of pregnancy. Women assigned to
      mefloquine IPT will receive mefloquine three times during pregnancy. Women randomised in this
      arm and having a low CD4 cell count or an advanced HIV disease will also receive
      cotrimoxazole prophylaxis in prevention of HIV/AIDS opportunistic infections. Drug efficacy
      will be judged on the prevalence of placental malaria at delivery.

      This study will contribute to updating the recommendations concerning the prevention of
      malaria during pregnancy in HIV-infected women.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of placental malaria (presence of parasites in the placental blood smear at delivery)</measure>
    <time_frame>delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>placental malaria mean parasite density at delivery</measure>
    <time_frame>delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of low birth weight infants (&lt;2500 g) and mean birth weight</measure>
    <time_frame>delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of maternal anaemia (&lt;11g/dl) and severe maternal anaemia (&lt;8g/dl) at delivery and during pregnancy</measure>
    <time_frame>course of pregnancy and delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cord blood malaria infection at delivery (infant parasitemia)</measure>
    <time_frame>delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pre-term deliveries (&lt; 37 weeks)</measure>
    <time_frame>delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>spontaneous abortions (early:&lt;28 weeks, late: ≥28 weeks) and still births</measure>
    <time_frame>course of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>congenital anomalies</measure>
    <time_frame>first 6 months of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety profile of the two treatments: proportion and detailed description of adverse effects in each treatment arm</measure>
    <time_frame>course of pregnancy (mother) anf first 6 months of life (infant)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mother-to-child HIV transmission rate in each treatment arm</measure>
    <time_frame>2 months after breastfeeding cessation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To document the effect of cotrimoxazole in reducing infections in HIV-infected women, we will measure the incidence of bacterial and parasitic infections (other than malaria) during pregnancy</measure>
    <time_frame>course of pregnancy</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">430</enrollment>
  <condition>Malaria in Pregnancy</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>cotrimoxazole (high)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD4 cell count≥350/mm3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mefloquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CD4 cell count≥350/mm3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cotrimoxazole (low)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD4 cell count&lt;350/mm3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mefloquine &amp; cotrimoxazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CD4 cell count&lt;350/mm3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cotrimoxazole</intervention_name>
    <description>800 mg sulfamethoxazole and 160 mg trimethoprim daily, from 28 weeks of gestation until delivery</description>
    <arm_group_label>cotrimoxazole (high)</arm_group_label>
    <arm_group_label>cotrimoxazole (low)</arm_group_label>
    <arm_group_label>mefloquine &amp; cotrimoxazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mefloquine</intervention_name>
    <description>mefloquine 15 mg/Kg three times, between 16 and 28 weeks, 24 and 32 weeks, then 28 and 36 weeks of pregnancy</description>
    <arm_group_label>mefloquine</arm_group_label>
    <arm_group_label>mefloquine &amp; cotrimoxazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed HIV seropositivity

          -  Permanent residency in the study catchment's area

          -  Confirmed pregnancy, gestational age&lt; 28 weeks

          -  More than 18 years of age

          -  Karnofsky index ≥80

          -  Willingness to deliver at the hospital

          -  Written informed consent

        Exclusion Criteria:

          -  History of allergy to study drugs : sulpha drugs, mefloquine, quinine

          -  History or presence of major illnesses : severe renal disease , severe hepatic
             disease, severe neuropsychiatric disease

          -  Mefloquine or halofantrine received within the 4 weeks prior to enrolment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcel D Zannou, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cotonou University Hospital &amp; Faculté des Sciences de la Santé, Benin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre-Marie Girard, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Saint Antoine Hospital, Assistance Publique-Hôpitaux se Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Cot, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Institut de Recherche pour le Developpement</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Camp Guézo</name>
      <address>
        <city>Cotonou</city>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Mère et de l'Enfant Lagune</name>
      <address>
        <city>Cotonou</city>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de zone de Suru Lere</name>
      <address>
        <city>Cotonou</city>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unviversity Hospital Hubert Koutoukou Maga</name>
      <address>
        <city>Cotonou</city>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Louis Pasteur</name>
      <address>
        <city>Porto-Novo</city>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Benin</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2009</study_first_submitted>
  <study_first_submitted_qc>September 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2009</study_first_posted>
  <last_update_submitted>January 21, 2013</last_update_submitted>
  <last_update_submitted_qc>January 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut de Recherche pour le Developpement</investigator_affiliation>
    <investigator_full_name>Lise Denoeud-Ndam</investigator_full_name>
    <investigator_title>MD, MPH</investigator_title>
  </responsible_party>
  <keyword>malaria</keyword>
  <keyword>pregnancy</keyword>
  <keyword>HIV</keyword>
  <keyword>prevention</keyword>
  <keyword>cotrimoxazole</keyword>
  <keyword>mefloquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mefloquine</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

